Alphanso’s AI Stock Research picked LLY as one of the top stocks of the year.
Alphanso Rating: 9.6/10
Return Potential: 20%
LLY (Eli Lilly and Company) pick stands out due to its global leadership in a diverse range of medications, including those for diabetes, cancer, autoimmune diseases, mental health, and more.
Fundamental Metrics:
- Revenue growth (fwd) of 11% vs. 9% sector median and EBITDA growth (fwd) of 13% vs. 6% sector median suggests that its products and services are highly competitive.
- The ROE of 66% vs. sector median of -43% indicates that its management is highly efficient and shareholder-friendly.
- The Beta of the stock is 0.5 which means it has low volatility and is relatively less risky, which is ideal to hold in the current economic environment.
- The bulk retail outlet has made it clear that it intends to redirect most excess profits and cash into extending its price-advantage lead in the industry but has lately re-announced dividends.
- $LLY has beaten earnings expectations 70% of the time in the past 15 years.
Technical Metrics:
Based on the Alphanso model, the stock is trading below the expected channel (range) of $684.1 – $723.6
